Intimation of alteration in the MOA and change of CIN
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
A-1 Limited (formerly A-1 Acid Limited) has received approval from the Registrar of Companies (ROC) for altering its object clause in the Memorandum of Association, following shareholder approval via postal ballot on December 21, 2025. The alteration, certified on January 27, 2026, adds two new main objects: (1) importing, exporting, trading, and marketing of sports equipment and accessories, and (2) manufacturing, sourcing, and distributing pharmaceutical products, drug intermediates, nutraceuticals, and healthcare products. As a result, the company's CIN has changed from L24119GJ2004PLC044011 (reflecting its earlier chemical/acid business) to L93190GJ2004PLC044011 / L46909GJ2004PLC044011. This represents a significant diversification away from its legacy chemical business into sports goods and pharmaceutical/healthcare segments.
This is a major strategic pivot for shareholders — the company is diversifying beyond its legacy acid/chemical operations into sports equipment and pharmaceutical manufacturing, which could open new revenue streams but also introduces execution risk in unfamiliar sectors. The CIN change signals to regulators, lenders, and counterparties that the company's core business identity has formally shifted.